Millennium Management LLC Invests $1.39 Million in Translate Bio Inc (TBIO) Stock

Share on StockTwits

Millennium Management LLC acquired a new position in shares of Translate Bio Inc (NASDAQ:TBIO) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 109,651 shares of the company’s stock, valued at approximately $1,387,000. Millennium Management LLC owned 0.24% of Translate Bio as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Point72 Hong Kong Ltd purchased a new position in shares of Translate Bio in the 2nd quarter worth approximately $128,000. Luminus Management LLC purchased a new position in shares of Translate Bio in the 2nd quarter worth approximately $1,925,000. Laurion Capital Management LP purchased a new position in Translate Bio during the 2nd quarter valued at $822,000. DAFNA Capital Management LLC purchased a new position in Translate Bio during the 2nd quarter valued at $253,000. Finally, Key Square Capital Management LLC purchased a new position in Translate Bio during the 2nd quarter valued at $696,000. Institutional investors own 40.52% of the company’s stock.

TBIO opened at $5.63 on Thursday. Translate Bio Inc has a 52-week low of $5.00 and a 52-week high of $16.60.

Translate Bio (NASDAQ:TBIO) last posted its quarterly earnings data on Thursday, August 9th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.70 by ($3.64). Sell-side analysts anticipate that Translate Bio Inc will post -0.98 earnings per share for the current fiscal year.

A number of research firms recently issued reports on TBIO. Evercore ISI began coverage on Translate Bio in a report on Monday, July 23rd. They set an “outperform” rating and a $25.00 price objective for the company. Leerink Swann began coverage on Translate Bio in a report on Monday, July 23rd. They set an “outperform” rating and a $24.00 price objective for the company. Finally, Citigroup began coverage on Translate Bio in a report on Monday, July 23rd. They set a “buy” rating and a $20.00 price objective for the company.

Translate Bio Profile

Translate Bio, Inc, a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency.

Read More: What does cost of debt say about a company’s financial health?

Want to see what other hedge funds are holding TBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Translate Bio Inc (NASDAQ:TBIO).

Institutional Ownership by Quarter for Translate Bio (NASDAQ:TBIO)

Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply